OliX PharmaceuticalsInc (226950) — Cash Flow-to-Debt Ratio
OliX PharmaceuticalsInc (226950) has a Cash Flow-to-Debt Ratio of -0.14x as of March 2026, meaning its operating cash flow of ₩-5.72 Billion could theoretically repay 0% of its total liabilities (₩40.96 Billion) in one year. See 226950 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
OliX PharmaceuticalsInc Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for OliX PharmaceuticalsInc across 10 annual periods. For the full cash flow conversion analysis, see cash flow conversion of OliX PharmaceuticalsInc.
Annual Cash Flow-to-Debt Ratio for OliX PharmaceuticalsInc (2016–2025)
Year-by-year debt coverage analysis for OliX PharmaceuticalsInc. Check OliX PharmaceuticalsInc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.35x | ₩-15.90 Billion | ₩45.29 Billion | ▲ +33.1% |
| 2024 | -0.53x | ₩-28.04 Billion | ₩53.40 Billion | ▼ -30.2% |
| 2023 | -0.40x | ₩-21.17 Billion | ₩52.49 Billion | ▲ +12.3% |
| 2022 | -0.46x | ₩-30.68 Billion | ₩66.74 Billion | ▼ -64.4% |
| 2021 | -0.28x | ₩-19.05 Billion | ₩68.15 Billion | ▼ -147.6% |
| 2020 | -0.11x | ₩-3.76 Billion | ₩33.29 Billion | ▲ +96.4% |
| 2019 | -3.15x | ₩-10.73 Billion | ₩3.41 Billion | ▲ +73.7% |
| 2018 | -11.96x | ₩-8.36 Billion | ₩698.94 Million | ▼ -640.5% |
| 2017 | -1.62x | ₩-4.79 Billion | ₩2.96 Billion | ▼ -21.4% |
| 2016 | -1.33x | ₩-3.45 Billion | ₩2.59 Billion | — |